Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Has results × brolucizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Cyclophosphamide 203 pembrolizumab 169 Carboplatin 156 Cisplatin 147 Gemcitabine 140 Paclitaxel 138 Radiotherapy 124 Docetaxel 123 Bevacizumab 122 Rituximab 121 Dexamethasone 112 Nivolumab 110 fludarabine 93 Capecitabine 90 Fluorouracil 85 fludarabine phosphate 80 Doxorubicin 78 Pemetrexed 76 Oxaliplatin 71 Cytarabine 70 Etoposide 69 Leucovorin 67 Bortezomib 66 Erlotinib Hydrochloride 65 Filgrastim 63 Calcium Dobesilate 62 Lenalidomide 60 Irinotecan 60 Methotrexate 55 Granulocyte Colony-Stimulating Factor 55

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡